Case Study: Advanced Prostate Cancer Phase III Study

Two studies sought to evaluate the efficacy of the 15mg 4-month formulation or 22.5mg 6-month formulation in achieving castrate levels of testosterone (=1.735nmol/L) on Day 29 (i.e., 28 days after study drug injection).

The timelines for recruitment were short, but all of the patients for both studies were enrolled in half of the projected time. The Quintiles team worked extra hours to ensure that requests from the sponsor were met on time. Through close communication with the sponsor, and a robust presence and local expertise in South Africa, effort was made to ensure all of the customer's needs were met at all times.